Bone-modifying drugs
Prostate cancer patients face a significant problem with their bone health. Hormonal therapy can either cause or exacerbate bone conditions like osteoporosis and osteoopenia. The risk of fractures should be assessed for prostate cancer patients receiving ADT for non-metastatic disease. The most widely recognized method for finding an individual's gamble is with a double energy X-beam absorptiometry (DEXA) sweep to quantify the strength of the bones. Treatment should be given to those who are found to be at a high risk for a fracture. Bone-changing medications that can be utilized in this present circumstance incorporate denosumab (Prolia, Xgeva), zoledronic corrosive (Reclast, Zometa), alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), and pamidronate (Aredia). Talk to your doctor about when to take these medications and which is best for you based on your situation because they can have side effects. In patients who do not currently have evidence of bone metastase...